Citadel Advisors
CAPR icon

Citadel Advisors’s Capricor Therapeutics CAPR Stock Holding History

Citadel Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.2M Sell
336,500
-153,500
-31% -$4.09M ﹤0.01% 3224
2025
Q4 		$14.1M Sell
490,000
-255,600
-34% -$3.34M ﹤0.01% 2780
2025
Q3 		$5.38M Buy
745,600
+443,600
+147% +$3.27M ﹤0.01% 4232
2025
Q2 		$3M Buy
302,000
+38,400
+15% +$406K ﹤0.01% 4979
2025
Q1 		$2.5M Sell
263,600
-58,800
-18% -$816K ﹤0.01% 5111
2024
Q4 		$4.45M Buy
322,400
+238,500
+284% +$4.18M ﹤0.01% 4145
2024
Q3 		$1.28M Buy
83,900
+46,800
+126% +$231K ﹤0.01% 6365
2024
Q2 		$177K Buy
37,100
+16,200
+78% +$90.3K ﹤0.01% 10102
2024
Q1 		$142K Sell
20,900
-3,500
-14% -$16.9K ﹤0.01% 10846
2023
Q4 		$119K Buy
24,400
+3,000
+14% +$9.77K ﹤0.01% 10704
2023
Q3 		$73.2K Buy
21,400
+17,900
+511% +$101K ﹤0.01% 11276
2023
Q2 		$16.7K Sell
3,500
-41,300
-92% -$181K ﹤0.01% 12882
2023
Q1 		$189K Sell
44,800
-39,800
-47% -$171K ﹤0.01% 10278
2022
Q4 		$327K Buy
84,600
+4,700
+6% +$22.4K ﹤0.01% 9130
2022
Q3 		$479K Sell
79,900
-35,300
-31% -$181K ﹤0.01% 8543
2022
Q2 		$402K Buy
115,200
+29,500
+34% +$105K ﹤0.01% 9130
2022
Q1 		$294K Sell
85,700
-15,900
-16% -$62.7K ﹤0.01% 10636
2021
Q4 		$298K Sell
101,600
-41,800
-29% -$146K ﹤0.01% 10937
2021
Q3 		$576K Buy
143,400
+45,300
+46% +$206K ﹤0.01% 9531
2021
Q2 		$503K Buy
98,100
+48,700
+99% +$206K ﹤0.01% 10049
2021
Q1 		$231K Sell
49,400
-15,400
-24% -$88.7K ﹤0.01% 11425
2020
Q4 		$222K Buy
64,800
+32,200
+99% +$140K ﹤0.01% 9577
2020
Q3 		$171K Buy
+32,600
New +$190K ﹤0.01% 8926

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors's CAPR Position: Q1 2026 in Review

Citadel Advisors reduced its Capricor Therapeutics (CAPR) stake by 40% in Q1 2026, selling an estimated $9.67M and leaving 539,232 shares worth $16.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2579.

Citadel Advisors first reported a position in CAPR in Q3 2016 and has held it in 28 quarters since. The position peaked at $26M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Citadel Advisors held 539,232 shares of Capricor Therapeutics worth $16.4M as of Q1 2026.
  • Citadel Advisors sold 362,764 Capricor Therapeutics shares in Q1 2026, an estimated $9.67M.
  • Capricor Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2579 holding.
  • Citadel Advisors first reported a position in Capricor Therapeutics in Q3 2016 and has held it in 28 quarters since.
  • Citadel Advisors's Capricor Therapeutics position peaked at $26M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.